ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 963,75
0,62%
Dow Jones
38 225,66
0,85%
DAX
17 979,00
0,41%
Brent Oil
83,55
-0,10%
Bitcoin
59 401,08
0,47%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Kymera Therapeutics Inc (KYMR)

  7. Kymera Therapeutics Inc (KYMR) Actualités

KYMR Kymera Therapeutics Inc

36,30
0,00 (0,00%)
Avant marché
Dernière mise à jour : 10:05:51
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Kymera Therapeutics Inc KYMR NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 36,30 10:05:51
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
36,30
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
02/5/202413:00GLOBEKymera Therapeutics Announces First Quarter 2024 Financial..
25/4/202413:00GLOBEKymera Therapeutics to Report First Quarter 2024 Financial..
08/4/202413:00GLOBEKymera Therapeutics Announces Scientific Presentations at..
08/3/202416:00GLOBEKymera Therapeutics Presents Preclinical Data for STAT6 and..
05/3/202400:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202400:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202400:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202423:50EDGAR2Form 144 - Report of proposed sale of securities
04/3/202423:47EDGAR2Form 144 - Report of proposed sale of securities
28/2/202413:00GLOBEKymera Therapeutics to Participate in Upcoming March..
27/2/202422:22EDGAR2Form 144 - Report of proposed sale of securities
22/2/202413:32EDGAR2Form S-8 - Securities to be offered to employees in employee..
22/2/202413:10EDGAR2Form 8-K - Current report
22/2/202413:00GLOBEKymera Therapeutics Announces Fourth Quarter and Full Year..
15/2/202413:00GLOBEKymera Therapeutics to Report Fourth Quarter and Full Year..
10/2/202401:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:22EDGAR2Form 144 - Report of proposed sale of securities
31/1/202413:00GLOBEKymera Therapeutics to Present in Fireside Chat at the..
09/1/202415:17GLOBEKymera Therapeutics Outlines Key 2024 Objectives and..
09/1/202415:15GLOBEKymera Therapeutics Announces Closing of Upsized $275..
05/1/202422:11EDGAR2Form 8-K - Current report
05/1/202422:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/1/202412:00GLOBEKymera Therapeutics Announces Pricing of $275 Million Public..
04/1/202422:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/1/202422:01GLOBEKymera Therapeutics Announces Proposed Public Offering
04/1/202413:08EDGAR2Form 8-K - Current report
04/1/202413:00GLOBER&D Day Highlights Kymera’s Immunology Strategy and Emerging..
02/1/202423:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202413:00GLOBEKymera Therapeutics to Present at the 42nd Annual J.P...
13/12/202313:00GLOBEKymera Therapeutics to Host Virtual Immunology R&D Day on..
11/12/202303:00GLOBEKymera Therapeutics Presents Interim Results from STAT3..
07/12/202313:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
13/11/202317:00GLOBEKymera Therapeutics Announces Publication of Phase 1 Trial..
07/11/202300:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202314:15EDGAR2Form 8-K - Current report
02/11/202314:00GLOBEKymera Therapeutics to Present New Clinical Data from the..
02/11/202312:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202312:10EDGAR2Form 8-K - Current report
02/11/202312:00GLOBEKymera Therapeutics Announces Third Quarter 2023 Financial..
01/11/202312:00GLOBEKymera Therapeutics to Participate in Upcoming November..
27/10/202313:00GLOBEKymera Therapeutics Announces First Patient Dosed in Phase 2..
26/10/202313:00GLOBEKymera Therapeutics to Report Third Quarter 2023 Financial..
16/10/202313:00GLOBEKymera Therapeutics Presents Preclinical Data Demonstrating..
18/9/202313:00GLOBEKymera Therapeutics Receives U.S. FDA Fast Track Designation..
08/8/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202313:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202313:10EDGAR2Form 8-K - Current report
03/8/202313:00GLOBEKymera Therapeutics Announces Second Quarter 2023 Financial..
27/7/202313:00GLOBEKymera Therapeutics to Report Second Quarter 2023 Financial..
22/6/202315:21DJNKymera Therapeutics Gets Orphan-Drug Status for Leukemia..

Dernières Valeurs Consultées

NASDAQ
KYMR
Kymera Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés